Moderna stock slides 14% premarket after profit and revenue fall short of estimates and biotech offers soft guidance
Moderna Inc. shares slid 14% in premarket trade Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and said short-term supply constraints would impact 2022 advance purchase agreements. The Cambridge, Mass.-based biotech posted net income of $1.043 billion, or $2.53 a share, for the quarter, down from $3.333 billion, or $7.70 a share, in the year-earlier period. Revenue fell to $3.364 billion from $4.969 billion a year ago. Both numbers were below the FactSet consensus... Читать дальше...

